Nationwide collection of consumables, the director of the National Medical Insurance Bureau speaks

Medical Network News on March 1
visited a number of top three to investigate high-value consumables.

On February 25, according to the Sichuan Medical Insurance Bureau, from February 22 to 23, Hu Jinglin, Secretary of the Party Leadership Group and Director of the National Medical Security Bureau, led a team to Sichuan The province has carried out research on the centralized procurement of high-value medical consumables
.
Hu Jinglin and his entourage visited West China Hospital of Sichuan University, West China Stomatological Hospital of Sichuan University, Sichuan Orthopedic Hospital, Sichuan Kelun Pharmaceutical Co.
, Ltd.
, focusing on the production and use of related drugs and medical consumables
.
At the same time, it organized a symposium on the centralized procurement of medicines and equipment by some provinces (autonomous regions and municipalities) medical security bureaus and medical institutions.
Hu Jinglin and his party listened to reports on the centralized procurement of medicines and high-value medical consumables in Sichuan Province, Jiangsu Province, and Inner Mongolia Autonomous Region.
West China Hospital of Sichuan University, Provincial Orthopaedic Hospital, West China Stomatological Hospital of Sichuan University related opinions and suggestions on the collection of orthopedic consumables and oral consumables
.
Hu Jinglin pointed out that since the state organized the reform of centralized procurement of medicines and medical consumables, significant results have been achieved, and it has played an important role in improving people's livelihood and welfare, promoting the reform of the three-medicine linkage, and promoting the healthy development of the pharmaceutical industry
.
Medical security departments at all levels must adhere to the linkage between top and bottom to build a new pattern of centralized procurement of pharmaceutical consumables, normalize and institutionalize centralized procurement of pharmaceuticals and medical consumables, and promote the coordination and coordination of national centralized procurement, provincial centralized procurement, and cross-regional alliance procurement.
Advance and continuously consolidate the results of reforms, and effectively enhance the people's sense of gain, happiness, and security
.
It is understood that on November 9, 2020, the national organization of the medical consumables joint procurement platform issued a notice of selection, and the coronary stent products of 8 medical equipment companies including Lanfan Medical, Esun Technology, Minimally Invasive Medical, Lepu Medical, and Medtronic were officially selected.
, The average price of domestic products was reduced by 92%, and the average price of imported products was reduced by 95%
.
The winning price of 3 machinery companies was less than 600 yuan, and a total of 4,24946 million coronary stents were selected; the winning price of 5 machinery companies was between 600-700 yuan, and a total of 339,711 were selected.

.
On December 3, 2020, according to Xinhua News Agency, the second batch of national centralized procurement of high-value medical consumables has been brewing
.
A red-headed document of "Notice on Carrying out the Second Batch of Centralized Procurement Data Collection and Price Monitoring of High-Value Medical Consumables" shows that the rapid collection of the first batch of medical consumables list data has been completed in the early stage, and now it is decided to start the second batch of medical consumables Quick collection of purchase data and price monitoring in a centralized list
.
The list mainly includes six categories of artificial hip joints, artificial knee joints, defibrillators, occluders, orthopedic materials, and staplers, involving more than 10,000 product information, including about 320,000 specifications and models
.

　　Normalization of volume purchases
Hu Jinglin emphasized that it is necessary to normalize and institutionalize the centralized volume purchase of medicines and medical consumables
.
Prior to this, on January 28, the State Council issued the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Centralized Drug Purchases
.
" The above-mentioned opinions also show that in accordance with the principle of basic and clinical protection, the focus will be to include drugs with large amounts and high purchase amounts in the basic medical insurance drug catalogue into the procurement scope, and gradually cover all kinds of clinically necessary and reliable drugs on the domestic market.
It should be full of excitement
.
It is also required to improve the settlement method
.
It is required that the time for medical institutions to settle the payment shall not exceed the end of the next month after the delivery and acceptance
.
At the same time, on the basis of the total budget of the medical insurance fund, a prepayment mechanism for centralized drug purchases will be established
.
According to the official website of the State Council, a regular policy briefing of the State Council was held on the afternoon of January 29.
Chen Jinfu, deputy director of the National Medical Security Administration, said that the procurement of medical consumables is a new area for the next round of reforms
.
In order to solve a series of problems in the consumables field due to high prices, chaotic sales, and a series of ecological deterioration, relevant departments have conducted explorations in the local areas under the guidance of the state, including Jiangsu, Anhui, Tianjin, and Tianjin as a representative.
A series of explorations on the "3+N" intraocular lens bidding model
.
In the future, we will still choose mature products, competitive products, and products with quality control, adopt a one-product-one-strategy approach, optimize campaign rules, and gradually expand in the field of medical consumables
.
Chen Song, a member of the Information Interaction and Integration Branch of the China Medical Equipment Association and a member of the Smart Medical Branch of the China Medical Materials Association, once published an article analysis in the "China Health" magazine.
The raw material costs and production costs of high-value medical consumables are actually not high, but the research and development investment is huge, and the sales The cost is even higher
.
For production companies , the "high pricing and high cost" marketing model cannot bring more profits to the company.
If the high market costs can be eliminated while obtaining sufficient sales guarantees, it will not actually affect the production companies’ performance.
Normal development, on the contrary, can obtain a better environment for survival and development due to simplified marketing
.

　　The core needs of the national centralized procurement, or the price reduction
, the relevant person in charge of Jiangsu Huazhao Network Information Technology Co.
, Ltd.
has published an article to analyze the national centralized procurement of coronary stents
.
The above article shows that in view of the sufficient preliminary preparations, the national centralized procurement competition rules for coronary stents are relatively simple, and there are three "no"s in the core points
.
First, no grouping
.
The 27 products negotiated by the country did not have a quality level.
The main reasons are two aspects: first, the coronary stents selected by the country negotiated have limited materials and drug loading conditions, and the performance of the products of each company is almost the same; second, there are many in the negotiation list After local negotiations, the prices of the products have basically been below 10,000 yuan
.
Second, do not negotiate
.
The registration certificate is used as the purchase unit for the only quotation.
After the price is declared, the price will not be modified or negotiated.
In the face of the national market share, a quotation directly determines whether the product will stay or stay, which will test the company's determination to reduce prices
.
Third, no more than 1.
8 times the minimum declared price (2850 yuan)
.
This fusing mechanism can effectively avoid the problem of large price differences between the selected products; and 2,850 yuan is the lowest negotiated price of a coronary stent from Lepu Medical based on Jiangsu drug-eluting coronary stents
.
These three "no"s reflect the core demand of the country's volume procurement: price reduction
.
Because the country fully understands that dozens of products currently selected can be used clinically instead of each other.
Under these conditions, the price has become the only criterion for the elimination of competition
.
Compared with national centralized procurement, cross-regional alliances have a higher frequency of centralized procurement and involve more consumables.
For example, Shaanxi 10-provincial alliance, Beijing-Tianjin-Hebei 3+N alliance, Guangdong 8-provincial alliance, etc.
, in alliance procurement, How to group has always been a topic of discussion in the industry
.
Recently, the International Pharmaceutical Business School of China Pharmaceutical University published an analysis in the "China Health Insurance" magazine.
Different grouping criteria may lead to different bid winning results, involving fairness, and consumables are more difficult to classify than drugs
.
For the same category of consumables, it is recommended to refer to the Beijing-Tianjin-Hebei and Heiji Liaomeng Jinlu (3+6) alliance, and list each attribute involved in the category of products as one item, and each attribute with the same attribute as a group.
This classification method is more detailed and can effectively avoid omissions
.
You can also refer to the grouping method of sets in Anhui Province.
Each treatment measure is a set.
All consumables required for the treatment measure are combined to form a set.
The price is negotiated in the set way.
The company needs to accept the bargaining of all component products in the set to ensure The products in each set that are successfully negotiated can be combined to meet clinical use
.
Currently, most of the methods used by the cross-regional alliance to determine the companies to be selected are negotiation and bidding.
The lowest price is still the most important selection principle
.